Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03275350 · ClinicalTrials.gov registry record · Phase 2
Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up
A Phase 2 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 2
- Development phase
- 114
- Enrollment target
NCT03275350 is a Phase 2 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 114 participants.
The verdict
NCT03275350, a Phase 2 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 114 participants
- Enrollment target
Study Summary
The Primary Objective of this study is to compare the effectiveness of HIV clinic-based extended-release Naltrexone (XR-NTX) in decreasing substance use and increasing HIV viral suppression in HIV-infected participants with opioid use disorder to Treatment as Usual in this population.
Interventions
- OTHER Treatment as usual
- DRUG Naltrexone Injectable Suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2018-02-05 |
| Est. Completion | 2019-11-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03275350
The ClinicalTrials.gov registry entry for NCT03275350 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Treatment as usual is the first listed.
NCT03275350 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03275350 about?
NCT03275350 is a clinical study titled "Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up". The Primary Objective of this study is to compare the effectiveness of HIV clinic-based extended-release Naltrexone (XR-NTX) in decreasing substance use and increasing HIV viral suppression in HIV-infected participants with opioid use disorder to Treatment as Usual in this population.
What is the current status of trial NCT03275350?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2018-02-05. Estimated completion is 2019-11-08.
What interventions are being tested in trial NCT03275350?
The interventions under investigation include: Treatment as usual (OTHER), Naltrexone Injectable Suspension (DRUG).
Who is sponsoring clinical trial NCT03275350?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.